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Abstract
Background: The gram-negative bacterium Bordetella pertussis is an important causative agent of
pertussis, an infectious disease of the respiratory tract. After introduction of whole-cell vaccines
(wP) in the 1950's, pertussis incidence has decreased significantly. Because wP were found to be
reactogenic, in most developed countries they have been replaced by acellular vaccines (aP). We
have previously shown a role for Toll-like receptor 4 (Tlr4) in pertussis-infected mice and the
pertussis toxin (Ptx)-IgG response in wP-vaccinated children, raising the issue of the relative
importance of Tlr4 in wP vaccination of mice. Here we analyze the effects of wP and aP vaccination
and B. pertussis challenge, in Tlr4-deficient C3H/HeJ and wild-type C3H/HeOuJ mice. aP consists of
Ptx, filamentous hemagglutinin (FHA), and pertactin (Prn).
Results: We show an important role of Tlr4 in wP and (to a lesser extent) aP vaccination,
induction of Th1 and Th17 cells by wP but not aP vaccination, and induction of Th17 cells by
infection, confirming data by Higgins et al. (J Immunol 2006, 177:7980–9). Furthermore, in Tlr4-
deficient mice, compared to wild-type controls (i) after vaccination only, Ptx-IgG (that was induced
by aP but not wP vaccination), FHA-IgG, and Prn-IgG levels were similar, (ii) after infection (only),
lung IL-1α and IL-1β expression were lower, (iii) after wP vaccination and challenge, Prn-IgG level
and lung IL-5 expression were higher, while lung IL-1β, TNF-α, IFN-γ, IL-17, and IL-23 expression
were lower, and lung pathology was absent, and (iv) after aP vaccination and challenge, Prn-IgG level
and lung IL-5 expression were higher, while Ptx-IgG level was lower.
Conclusion: Tlr4 does not influence the humoral response to vaccination (without challenge),
plays an important role in natural immunity, wP and aP efficacy, and induction of Th1 and Th17
responses, is critical for lung pathology and enhances pro-inflammatory cytokine production after
wP vaccination and challenge, and diminishes Th2 responses after both wP and aP vaccination and
challenge. wP vaccination does not induce Ptx-IgG. A role for LPS in the efficacy of wP underlines
the usefulness of LPS analogs to improve bacterial subunit vaccines such as aP.
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Background
Bordetella pertussis is an important causative agent of per-
tussis, which is among the ten infectious diseases with the
highest morbidity and mortality worldwide. After intro-
duction of whole-cell vaccines (wP) in the 1950's, pertus-
sis incidence has decreased significantly. Although
efficacious, wP vaccines were also found to be reactogenic.
Therefore, acellular vaccines (aP) comprising purified B.
pertussis proteins have been developed.
Toll-like receptor 4 (Tlr4) is the receptor for lipopolysac-
charide (LPS) in mammals [1]. Since B. pertussis is a gram-
negative bacterium, Tlr4 is likely to play an important role
in natural immunity to B. pertussis infection. Indeed, we
and others have shown that Tlr4 is critical for B. pertussis
clearance and ensuing adaptive immunity in non-vacci-
nated mice [2-4]. Furthermore, Tlr4 influenced lung
pathology and production of proinflammatory cytokines,
such as IL-1β and TNF-α, after B. pertussis infection [4].
Since wP are prepared from B. pertussis and (thus) contain
LPS it may be suggested that Tlr4 influences wP efficacy.
In our model of wP and aP vaccination and B. pertussis
challenge, lung pathology and TNF-α expression were
induced by vaccination (in particular with wP) and chal-
lenge [5]. Also, type I hypersensitivity, a Th2 driven
response, was induced by vaccination (with both wP and
aP) and challenge [5]. In that study, however, a role for
Tlr4 was not addressed.
We have identified an association of the minor allele of
rs2770150 in TLR4 with a lower pertussis toxin (Ptx)-IgG
level in wP-vaccinated children [6]. The mouse and
human studies together prompted us to analyze the rela-
tive role of Tlr4 in wP vaccination of mice.
Here we show that Tlr4 plays an important role in natural
immunity, wP and (to a lesser extent) aP efficacy, and
induction of Th1 and Th17 responses, confirming obser-
vations by Higgins et al. [7]. Moreover, we show that the
humoral response to vaccination (without challenge) is
not influenced by Tlr4 (wP vaccination did not induce
detectable Ptx-IgG). Tlr4 is critical for lung pathology and
enhances pro-inflammatory cytokine production after wP
vaccination and challenge, and diminishes Th2 responses
after both wP and aP vaccination and challenge.
Results
B. pertussis colonization of the lungs
Tlr4-deficient C3H/HeJ and wild-type control C3H/
HeOuJ mice (6 per group) were vaccinated twice with 1/5
human dose (HD) wP, 1/5 HD aP, or adjuvant, and chal-
lenged intranasally with B. pertussis. Three and seven days
after infection, mice were sacrificed and the number of
bacteria in their lungs was determined. Vaccinated mice
generally showed a lower number of bacteria than adju-
vant-treated animals, while Tlr4-deficient mice generally
showed a higher number of bacteria than wild-type ani-
mals (Figure 1). Adjuvant-treated Tlr4-deficient mice
showed an increasing number of bacteria from day 3 till
day 7 (Δ log CFU = 0.28, P  = 0.029), while similarly
treated wild-type animals showed a decreasing number in
this time period (Δ log CFU = -1.09, P < 0.001). Tlr4-defi-
cient mice that were wP-vaccinated before challenge failed
to show a decreasing number of bacteria from day 3 till
day 7, while similarly treated wild-type animals did show
a decreasing number in this time period (Δ log CFU = -
3.33, P < 0.001). In aP-vaccinated mice of either strain the
number of bacteria was similar between day 3 and day 7.
These data show (i) the important role of Tlr4 in the nat-
ural defense to B. pertussis infection and confirms our ear-
lier findings [4], (ii) the important role of Tlr4 in wP-
induced clearance, and (iii) that vaccine-induced clear-
ance is faster after aP vaccination than after wP vaccina-
tion, regardless of the presence of Tlr4. This latter notion
is supported by the higher clearance in aP-vaccinated than
wP-vaccinated mice at day 3 but not day 7 in either mouse
strain.
Vaccination-induced protection, i.e. the difference in the
number of bacteria between vaccinated and control mice,
was lower in Tlr4-deficient mice than in wild-type animals
(P < 0.01), except for aP vaccination at day 7 where this
effect was not statistically significant (Δ log CFU = -1.23
and -2.19 (day 3, wP), -2.22 and -4.37 (day 3, aP), -1.15
and -4.43 (day 7, wP), and -1.99 and -3.48 (day 7, aP) for
Tlr4-deficient and wild-type mice, respectively).
Collectively, these data show that Tlr4 is not only
involved in the natural defense to B. pertussis infection but
also in vaccination-induced protection to this pathogen,
both after wP and after aP vaccination.
Ptx-, FHA-, and Prn-specific IgG
Serum was taken 2 hours before challenge and 3 and 7
days after challenge, and analyzed for IgG specific for Per-
tussis toxin (Ptx), filamentous hemagglutinin (FHA), and
Pertactin 1 (Prn). Ptx-IgG was detectable only in aP-vacci-
nated mice (Figure 2). Before challenge the Ptx-IgG level
was not affected by Tlr4. At days 3 and 7 after challenge
Tlr4-deficient aP-vaccinated mice showed a significantly
lower Ptx-IgG level than similarly treated wild-type ani-
mals. In each mouse strain the Ptx-IgG level was similar
before and after challenge.
FHA-IgG was detectable in both wP- and aP-vaccinated
mice. aP-vaccinated mice showed a higher FHA-IgG level
than wP-vaccinated animals (irrespective of challenge).
Both before and after challenge the FHA-IgG level was notBMC Immunology 2008, 9:21 http://www.biomedcentral.com/1471-2172/9/21
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affected by Tlr4. Generally, both wP- and aP-vaccinated
wild-type but not Tlr4-deficient mice showed a lower
FHA-IgG level after challenge than before.
Prn-IgG was detectable in both wP- and aP-vaccinated
mice. Generally, aP-vaccinated mice showed a higher Prn-
IgG level than wP-vaccinated animals. Before challenge
the Prn-IgG level was not affected by Tlr4. Rather unex-
pectedly after challenge the Prn-IgG level was higher in
wP- and aP-vaccinated Tlr4-deficient mice than in simi-
larly treated wild-type animals.
Collectively, these data show that before challenge Tlr4
does not affect vaccination-induced Ptx-, FHA-, and Prn-
IgG levels. After challenge, the Ptx-IgG level is lower in
Tlr4-deficient mice than in wild-type animals, while the
reverse is true for Prn-IgG. The FHA-IgG level is unaffected
by the Tlr4 mutation.
Weight gain
Mice were weighed immediately before challenge, and 3
and 7 days after challenge (Figure 3). Paired sample test-
ing revealed weight loss of adjuvant controls; this was sig-
nificant in case of Tlr4-deficient mice at day 3 (P < .003)
and a trend in other cases. Weight gain was seen in wP-
but not aP-vaccinated Tlr4-deficient mice at days 3 and 7,
and in wP- and aP-vaccinated wild-type animals at day 7.
Weight gain in wP- and aP-vaccinated Tlr4-deficient mice
was higher than in adjuvant controls at days 3 and 7,
while in wP- and aP-vaccinated wild-type animals this was
the case only at day 7. A lower weight gain due to the Tlr4
mutation was seen only in aP-vaccinated mice at day 7.
Taken together, these data show that vaccination but not
(or to a much lesser extent) Tlr4 affects weight gain during
the first 7 days after B. pertussis challenge.
Colonization of the lungs by B. pertussis Figure 1
Colonization of the lungs by B. pertussis. Tlr4-deficient C3H/HeJ and control C3H/HeOuJ mice were subcutaneously (sc) 
injected with 1/5 human dose (HD) wP, aP, or adjuvant (C), twice before intranasal B. pertussis infection. Three and seven days 
after challenge lungs were excised, and the number of viable B. pertussis was determined in right lung lobes. Each symbol repre-
sents the number of bacteria in the lung of an individual mouse; horizontal lines represent the group average. Non-boxed P-val-
ues: compared to the indicated treatment group (same strain and day after infection). Boxed P-values: compared to the wild-
type strain (same treatment and day after infection). ANOVA followed by Bonferroni post-hoc test. A single representative 
experiment of 2 is shown.
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Ptx-, FHA-, and Prn-specific IgG in serum Figure 2
Ptx-, FHA-, and Prn-specific IgG in serum. Tlr4-deficient and control mice were sc injected with 1/5 HD wP, aP, or adju-
vant (C), twice before intranasal B. pertussis infection. Two hours before challenge, and three and seven days after challenge 
blood was taken. Test and positive control sera were tested for Ptx-, FHA-, and Prn-specific IgG. Each symbol represents the 
serum level of an individual mouse; horizontal lines represent the group average. (#) increased compared to the adjuvant con-
trol (same strain and time point; P < 0.001), (+) increased compared to wP-vaccinated mice (same strain and time point; P < 
0.001). Non-boxed P-values: compared to the indicated group (same strain and time point), boxed P-values: compared to the 
wild-type strain (same treatment and time point), and stippled-boxed P-values: compared to the pre-challenge level (same 
strain and treatment). ANOVA followed by Bonferroni post-hoc test. A single representative experiment of 2 is shown.
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Histological changes
We have previously shown that after challenge wP- and
aP-vaccinated mice revealed increased lung pathology
compared to adjuvant-treated animals, with wP-vacci-
nated mice showing more severe pathology than aP-vacci-
nated animals [5]. Here we addressed whether Tlr4
influenced lung pathology.
Lung lesions were scored 3 days after challenge (Figure 4).
In wild-type mice wP vaccination resulted in a stronger
challenge-induced peribronchiolitis, perivasculitis, and
alveolitis compared to adjuvant treatment and aP vaccina-
tion, rather similar to our previous findings [5]. Chal-
lenge-induced alveolitis was weaker in wP- and aP-
vaccinated Tlr4-deficient mice and in aP-vaccinated wild-
type animals, compared to their adjuvant controls. No
treatment effects on hypertrophy of the bronchiolar
mucous cells were seen in either strain, while eosinophilia
was absent in all groups.
Challenge-induced lung pathology was less severe in Tlr4-
deficient wP-vaccinated mice than in similarly treated
wild-type animals. No effect of the Tlr4 mutation was seen
after challenge of aP-vaccinated and adjuvant-treated
mice.
These data show that challenge-induced pathology in wP-
vaccinated animals is Tlr4-dependent.
Cytokine gene expression in lung tissue
B. pertussis infection induced TNF-α, IL-6, and IL-1β pro-
duction and Tlr4 was shown to play a role in this process
[2-4]. Thus, proinflammatory cytokines were analyzed.
Next, wP-vaccination induced Th1 and Th17 cells, these
cells were critical for clearance and their induction was
shown to be dependent on Tlr4 [7]. Thus, Th1 and Th17
cytokines were analyzed. Finally, pertussis vaccination (in
particular aP vaccination) before challenge induced a Th2-
dependent response [5] and this response could be
skewed towards a Th1 response by adding LPS analogs [8].
Thus, Th2 cytokines were analyzed.
Post-challenge lung lobes were subjected to real-time
PCR. The fold change is relative to lung tissue of untreated
C57BL/6J mice. Irrespective of prior vaccination, IL-1α
mRNA expression is lower in challenged C3H mice than
in untreated C57BL/6 mice, while the reverse is true for
the other cytokines analyzed.
Proinflammatory cytokines
Generally, in both strains of mice wP and aP vaccination
resulted in lower challenge-induced IL-1α, IL-1β, and
TNF-α expression than adjuvant treatment (Figure 5).
Tlr4-deficient adjuvant-treated mice showed higher chal-
lenge-induced IL-1α and IL-1β expression than similarly
treated wild-type animals at day 7. Tlr4-deficient wP-vac-
cinated mice showed lower challenge-induced IL-1β and
TNF-α expression than similarly treated wild-type animals
at day 3.
Gain of weight Figure 3
Gain of weight. Tlr4-deficient and control mice were sc injected with 1/5 HD wP, aP, or adjuvant (C), twice before intranasal 
B. pertussis infection. Two hours before challenge, and three and seven days after challenge mice were weighed. Data are indi-
cated as mean ± SEM (N = 6). Non-boxed P-values: compared to the adjuvant control (same strain and day after challenge). 
Boxed P-value: compared to the wild-type strain (same treatment and day after challenge). ANOVA followed by Bonferroni 
post-hoc test. A single representative experiment of 2 is shown.
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Lung pathology Figure 4
Lung pathology. Tlr4-deficient and control mice were sc injected with 1/5 HD wP, aP, or adjuvant (C), twice before intrana-
sal B. pertussis infection. Three days after infection the left lung lobes were excised. H&E staining. Histological lesions were 
semi-quantitatively scored as absent (0), minimal (1), slight (2), moderate (3), strong (4), or severe (5), respectively. Each sym-
bol represents an individual mouse; horizontal lines represent the group average. Non-boxed P-values: compared to the indi-
cated group (same strain). Boxed P-values: compared to the wild-type strain (same treatment). Mann-Whitney U test. A single 
representative experiment of 2 is shown.
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Th1/Th17 cytokines
Generally, in both strains of mice wP and aP vaccination
resulted in lower challenge-induced IFN-γ and IL-23
expression than adjuvant treatment, while for aP vaccina-
tion this was also seen for IL-17. Adjuvant-treated and aP-
vaccinated mice did not show Tlr4-dependent effects on
post-challenge Th1/Th17 cytokines. Tlr4-deficient wP-vac-
cinated mice did, however, show lower challenge-induced
IFN-γ, IL-17, and IL-23 expression than similarly treated
wild-type animals at day 3.
Th2 cytokines
Generally, in both strains of mice wP and aP vaccination
resulted in higher challenge-induced IL-4 and IL-5 expres-
Cytokine expression in lung Figure 5
Cytokine expression in lung. Tlr4-deficient and control mice were sc injected with 1/5 HD wP (|J|), aP (||), or adjuvant (| |), 
twice before intranasal B. pertussis infection. Three and seven days after challenge the left lung lobes were excised. RNA was 
extracted and analyzed by real-time PCR. The fold change in mRNA expression is relative to lung tissue of untreated C57BL/6J 
mice. Data are indicated as mean ± SEM (N = 6). Non-boxed P-values: compared to the adjuvant control, or (when indicated) 
wP-vaccinated group (same strain and day after challenge). Boxed P-values: compared to wild-type mice (same treatment and 
day after challenge). ANOVA followed by Bonferroni. A single representative experiment of 2 is shown.
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sion than adjuvant treatment. Adjuvant-treated mice did
not show Tlr4-dependent effects on post-challenge Th2
cytokines.  Tlr4-deficient aP-vaccinated mice showed
higher challenge-induced IL-5 expression than similarly
treated wild-type animals. This effect of the Tlr4 mutation
was also seen for wP-vaccinated mice at day 3.
In summary, in both strains of mice wP and aP vaccina-
tion resulted in lower challenge-induced IL-1α, IL-1β,
TNF-α, IFN-γ, IL-17, and IL-23 expression, and higher
challenge-induced IL-4 and IL-5 expression. Exceptions to
this overall picture were higher TNF-α and IL-17 expres-
sion in wP-vaccinated wild-type mice.
Tlr4 mediated (i) in adjuvant-treated mice, lower expres-
sion of IL-1α and IL-1β at day 7, (ii) in wP-vaccinated
mice, higher expression of IL-1β and TNF-α, and of Th1
and Th17 cytokines at day 3, and (iii) in wP- and aP-vac-
cinated mice, higher expression of IL-5 at days 3 and 7
after challenge.
In short, functional Tlr4 results in a lower lung inflamma-
tory response after infection, a higher inflammatory
response and Th1/Th17 response after wP vaccination
and challenge, and a lower Th2 response after wP and aP
vaccination and challenge.
Cytokine production by bronchial lymph node cells
Cell suspensions from post-challenge bronchial LN were
Con A-stimulated ex vivo. From the panel of cytokines
tested (IL-1α, IL-4, IL-5, IL-10, IL-13, IL-17, IFN-γ, and
TNF-α), IL-1α and IL-13 were excluded from further anal-
ysis because for these cytokines one or more of the treat-
ment groups showed concentrations below the detection
limit for 4 or more of the 6 samples tested.
Generally, vaccinated mice showed lower challenge-
induced IFN-γ and IL-17 production than adjuvant-
treated animals at day 7 (Figure 6). Tlr4-deficient adju-
vant-treated mice showed lower challenge-induced IFN-γ
and IL-17 production than similarly treated wild-type ani-
mals at day 7. Tlr4-deficient wP-vaccinated mice showed
lower challenge-induced IL-17 production than similarly
treated wild-type mice at day 3.
IL-4, IL-5, and IL-10 production was 13-, 11-, and 9-fold
higher, respectively, in wP-vaccinated than in adjuvant-
treated Tlr4-deficient mice at day 3 after challenge (P =
0.004, P = 0.028, and P = 0.015, respectively). No strain-
or additional treatment-related effects on the production
of these cytokines were seen. No strain- or treatment-
related effects on TNF-α production were seen (data not
shown).
Together, in bronchial LN cells functional Tlr4 results in a
higher Th1/Th17 response after infection. Moreover, in
these cells functional Tlr4 results in a higher Th17 and a
lower Th2 response after wP vaccination and challenge.
Cytokine production by splenocytes
Cell suspensions from post-challenge spleens were stimu-
lated ex vivo with heat-killed B. pertussis. From the panel of
cytokines tested (IL-1α, IL-4, IL-5, IL-10, IL-13, IL-17, IFN-
γ, and TNF-α), IL-1α, IL-4, IL-5, IL-13, IL-17, and IFN-γ
were excluded from further analysis because for these
cytokines one or more of the treatment groups showed
concentrations below the detection limit for 4 or more of
the 6 samples tested.
Vaccination did not affect challenge-induced IL-10 pro-
duction, while Tlr4-deficient mice showed lower chal-
lenge-induced production of this cytokine than wild-type
animals.  Tlr4-deficient adjuvant-treated mice showed
lower challenge-induced TNF-α production than similarly
treated wild-type animals at days 3 and 7, while Tlr4-defi-
cient wP-vaccinated mice showed lower challenge-
induced production of this cytokine than similarly treated
wild-type animals at day 7.
Together, these data show that in the spleen regardless of
vaccination functional Tlr4 results in a higher IL-10
response after infection. Functional Tlr4 also results in a
higher TNF-α response after infection, and after wP vacci-
nation and challenge.
Discussion
Here we have shown that after infection of non-vaccinated
Tlr4-deficient mice the number of bacteria, and lung IL-1α
and IL-1β expression are higher than in similarly treated
wild-type controls, while bronchial LN cell IFN-γ and IL-
17 production and splenocyte TNF-α production are
lower. Table 1 summarizes our findings. In non-vacci-
nated but also in vaccinated animals, before challenge no
effect of the Tlr4 mutation on Ptx-, FHA-, and Prn-IgG lev-
els is seen. After challenge of wP-vaccinated Tlr4-deficient
mice, the number of bacteria, Prn-IgG level, and lung IL-5
expression are higher compared to wild-type controls, and
lung pathology is diminished, while lung IL-1β, TNF-α,
IFN-γ, IL-17, and IL-23 expression and bronchial LN cell
IL-17 production are lower. After challenge of aP-vacci-
nated Tlr4-deficient mice the number of bacteria, Prn-IgG
level, and lung IL-5 expression are higher compared to
wild-type controls, while Ptx-IgG level and weight gain are
lower. Collectively, these data show an important role for
Tlr4 in infection, being bacterial clearance, induction of
pro-inflammatory cytokines, and induction of Th1 and
Th17 responses. Tlr4 is also important in the challenge
response after wP vaccination, being bacterial clearance
but also concomitant pathology, induction of pro-inflam-BMC Immunology 2008, 9:21 http://www.biomedcentral.com/1471-2172/9/21
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Ex vivo cytokine production by bronchial lymph node and spleen cells Figure 6
Ex vivo cytokine production by bronchial lymph node and spleen cells. Tlr4-deficient and control mice were sc 
injected with 1/5 HD wP (|J|), aP (||), or adjuvant (| |), twice before intranasal B. pertussis infection. Three and seven days after 
challenge the bronchial lymph nodes (LN) and spleens were excised and cell suspensions were made. Bronchial LN cells were 
cultured with Con A for 24 hr; spleen cells were cultured with heat-killed B. pertussis for 72 hr. Culture supernatants were ana-
lyzed for cytokine content by Luminex. Data are indicated as mean ± SEM (N = 6). Non-boxed P-values: compared to the adju-
vant control, or (when indicated) aP-vaccinated group (same strain and day after challenge). Boxed P-values: compared to wild-
type mice (same treatment and day after challenge). ANOVA followed by Bonferroni. A single representative experiment of 2 
is shown.
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matory cytokines, and induction of Th1, Th17, and Th2
responses. Tlr4 plays an important role also in the chal-
lenge response after aP vaccination, with a more limited
number of parameters affected, being bacterial clearance
and induction of the Th2 response. Our data confirm pre-
vious data by Higgins et al. [7], who showed an important
role of Tlr4 in induction of Th17 cells by infection, in bac-
terial clearance after wP- and aP-vaccination, and induc-
tion of Th1 and Th17 cells by wP but not aP vaccination.
Concerns have been raised with respect to the relative effi-
cacy of aP as compared to wP, and also of vaccines admin-
istered simultaneously with aP, such as diphtheria,
tetanus, polio, and Haemophilus influenzae b (Hib) vac-
cines [9]. A cause for the limited efficacy of aP may be that,
in contrast to wP, they do not contain LPS. In mice Th17
[10] and Th1 cells are induced by wP vaccination, but not
(or to a much lesser extent) by aP vaccination, and the
induction of these Th17 and Th1 cells is Tlr4-dependent
[7]. Importantly, Th17 and Th1 cells are critical for clear-
ing a B. pertussis challenge [7]. These findings show the
importance of Tlr4 (and hence, also its agonists such as
LPS) in generating immune responses induced by pertus-
sis vaccines, at least in mice. The efficacy of vaccines that
do not contain LPS, such as viral vaccines and bacterial
subunit vaccines can be improved by supplementation
with Tlr4 agonists that show no or little endotoxin activ-
ity. We have shown that supplementing the bacterial sub-
unit vaccine aP with the Tlr4 agonist monophosphoryl
lipid A improved its efficacy [8].
On day 3 after infection vaccinated mice had a lower
number of bacteria in their lungs than adjuvant controls.
This may have affected the cytokine levels measured.
Therefore, we plan to study cytokine responses earlier in
infection to determine their effects on bacterial clearance.
Our data show that Tlr4 affects the humoral response to
vaccination only after challenge. This suggests a Tlr4-
dependent effect of bacterial challenge on the humoral
response, and that Tlr4 plays a more important role in the
challenge phase than in the vaccination phase. Transfer
studies from vaccinated Tlr4-deficient mice to naive Tlr4-
sufficient animals and subsequent challenge, or studies
using conditional Tlr4-knockout mice should settle this
issue.
Our failure to detect Ptx-IgG in wP-vaccinated animals is
in line with observations in both humans [11] and mice
[12,13] that showed aP vaccines to induce a much higher
Ptx-IgG level than wP vaccines. In rather contrast to a pre-
vious report where Prn-IgG could be detected in convales-
cent serum from B. parapertussis but not B. pertussis
infected mice [14], we did observe Prn-IgG in vaccinated
mice. The lower FHA- and Prn-IgG levels after challenge
may be explained by Ptx-mediated suppression of serum
antibody levels after infection [15] or by binding of the
antibodies by the bacterial challenge.
We have identified an association of the minor allele of
rs2770150 in TLR4 with a lower Ptx-IgG level in wP-vacci-
nated children [6]. As we did not detect Ptx-IgG after wP
vaccination of mice, we cannot compare the data
obtained in humans to those in mice.
Here we show that Tlr4 plays an important role in lung
pathology induced by wP vaccination and challenge.
Until recently, it has been assumed that tissue damage is
mediated by Th1 cells [16]. We have previously shown,
however, that Th1 cells are not involved in lung pathology
induced by wP vaccination and challenge, as T-bet KO
mice that lack Th1 cells showed similar pathology com-
pared to wild-type controls [5], suggesting that a different
subset is involved. Possibly, Th17 cells may be the subset
responsible for this pathology, as these cells are important
Table 1: summary of Tlr4 mutation effects (Tlr4Lps-d vs. wild-type)
Pre-challenge Post-challenge Post-challenge Post-challenge
Non-vaccinated wP-vaccinated aP-vaccinated
Number of bacteria ↑↑ ↑
Ptx-IgG =1 ND3 ND ↓
FHA-IgG =2 ND = =
Prn-IgG =2 ND ↑↑
Weight gain = = ↓
Lung pathology = ↓ =
Pro-inflammatory cytokines4 ↑ ↓↓↓==
Th1/Th17 cytokines4 = ↓↓↓==
Th2 cytokines4 =N D ↑ ND ↑ ND
1Only aP-vaccinated mice showed detectable Ptx-IgG levels. 2Only wP- and aP-vaccinated mice showed detectable FHA-IgG and Prn-IgG levels. 
3ND, not detected. 4First symbol indicates mRNA expression; second symbol indicates production.BMC Immunology 2008, 9:21 http://www.biomedcentral.com/1471-2172/9/21
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in mediating tissue damage [16,17] and are induced by
wP vaccination in a Tlr4-dependent way [7]. Th17 cells are
induced in the presence of IL-6, while regulatory T-cells
are induced in the absence of this cytokine (in an other-
wise similar cytokine milieu) [17]. Possibly, induction of
IL-6 by wP vaccination [8] may play a role in the genera-
tion of Th17 cells. Whether indeed Th17 cells are respon-
sible for lung pathology after wP vaccination and
challenge awaits further study.
Our finding of infection-induced IL-17 production is in
line with the observation of IL-23 production by human
monocyte-derived DC after B. pertussis infection [18].
Since IL-23 is required for amplifying and/or stabilizing
Th17 cells [10], both findings suggest Th17 induction by
B. pertussis infection.
It is intriguing but also complicating that not only LPS but
also Ptx may play a role in the Tlr4-dependent induction
of Th17 cells. Ptx has Tlr4-dependent adjuvant activity
[19,20] and is able to induce Th17 cells [21]. It is likely,
but not formally proven, that this latter effect is Tlr4-
dependent (X. Chen, personal communication). Vaccina-
tion with wP that is derived from Ptx-deleted B. pertussis
may clarify this issue.
We show that production of IFN-γ and IL-17 by bronchial
LN cells from non-vaccinated Tlr4-deficient mice is lower
than from wild-type controls, in line with previous obser-
vations for IFN-γ [2] (IL-17 was not measured in that
study). This suggests that not only wP vaccination but also
B. pertussis infection induces Th1 and Th17 cells in a Tlr4-
dependent way.
IL-10 production by B. pertussis-stimulated splenocytes is
lower when these cells are obtained from Tlr4-deficient
mice than from wild-type controls. Challenge-induced
pathology is similar between adjuvant-treated Tlr4-defi-
cient mice and similarly treated wild-type controls, and
lower in wP-vaccinated Tlr4-deficient mice than in their
wild-type controls. Together, these data suggest that in our
model IL-10 is not involved in limiting pathology, in con-
trast to a study by others [2]. Our observations were made
at day 3 after challenge, however, whereas the other study
[2] made these observations at day 14–21.
A recent paper has shown that the number of bacteria in
the lungs of B. pertussis infected TNF-α deficient mice was
higher than in similarly treated wild-type controls [22]. In
our study, B. pertussis-stimulated splenocytes from
infected Tlr4-deficient mice produce less TNF-α than cells
from similarly treated wild-type controls. The lower sys-
temic TNF-α response observed in our study may contrib-
ute to the higher number of bacteria in the lungs of Tlr4-
deficient mice. It has to be noted, however, that the differ-
ences in bacterial numbers between TNF-α deficient mice
and their controls were not seen until day 10 after infec-
tion [22].
Two signal transduction pathways downstream of Tlr4
have been identified, the MyD88-dependent pathway and
the MyD88-independent (TRIF) pathway. The former
pathway involves the adaptor proteins TIRAP and MyD88,
the latter one TRIF and TRAM [23]. The bacterial species
from which LPS originates, determines the pathway(s)
activated [24]. Since wP is derived from B. pertussis, they
harbor the same LPS suggesting activation of the same
pathway. wP, however, consists of glutaraldehyde-fixed
bacteria, and its LPS may thus activate a different pathway
than LPS from live B. pertussis [25]. To study possible dif-
ferences in pathway activation, TRIF-deficient (C57BL/6J-
Ticam1Lps2/J [26]) and wild-type controls (C57BL/6J)
were compared in our model. TRIF-deficient mice are
readily available and are not deficient in other pathways
besides TRIF/TRAM, while MyD88 KO mice are not only
deficient in MyD88/TIRAP but also in the IL-1R and IL-
18R pathways [27]. Three days after infection, wP- and aP-
vaccinated mice showed a ~500-fold lower colonization
than non-vaccinated controls, and no differences in colo-
nization were seen between TRIF-deficient and wild-type
mice (data not shown). This shows that the TRIF pathway
is not involved in clearance of a B. pertussis infection, nor
is it involved in wP or aP vaccine-induced clearance.
TRIF-deficient mice are strongly impaired in LPS-induced
CD40, CD80, CD86, and MHC class II upregulation, as
well as type I IFN production in macrophages in vitro, and
CD40, CD80, and CD86 upregulation in CD11+ DC in
vivo. Also, the CD4+ and CD8+ T-cell response is abolished
when LPS is used as adjuvant [28]. Importantly, type I
interferons promote memory T-cell proliferation [29].
Thus, the lack of an effect of TRIF-deficiency suggests that
clearance of a B. pertussis infection, as well as wP- and aP-
induced immunity are also functional under conditions
of severely reduced costimulation and (memory) T-cell
responses. This lack of an effect of TRIF-deficiency also
suggests involvement of the MyD88-dependent pathway.
We set out to study this pathway, but breeding problems
with MyD88 KO mice prohibited these experiments. Still,
a role for MyD88 is likely from a study by Togbe et al. [30]
who showed a TIRAP- and MyD88-dependent TRIF-inde-
pendent response to LPS in the lungs, including Th1
cytokine production and neutrophil influx. Both parame-
ters are characteristic of B. pertussis challenge, as well as of
wP but not aP vaccination and similar challenge [12,31].
Conclusion
We have shown that Tlr4 does not affect the humoral
response to vaccination. Tlr4 is important in (i) natural
defense to B. pertussis infection, and also in wP and aP vac-BMC Immunology 2008, 9:21 http://www.biomedcentral.com/1471-2172/9/21
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cination-induced clearance, (ii) challenge-induced lung
pathology after wP vaccination, (iii) induction of Th1 and
Th17 responses by B. pertussis infection and also by wP
vaccination and challenge, and (iv) reduced Th2 response
after wP and aP vaccination and challenge. A summary of
our findings is presented in Figure 7.
Methods
Animals
Female mice were used at 6–8 weeks of age. Tlr4Lps-d C3H/
HeJ [32] and wild-type control C3H/HeOuJ mice were
obtained from Jackson (Bar Harbor, ME). The diet con-
sisted of ground standard laboratory chow (RMH-B, Hope
Farms, Woerden, the Netherlands). Food and water were
given ad libitum. All animal experiments were performed
according to national and international guidelines.
Vaccines
The wP vaccine is a whole-cell pertussis vaccine, com-
bined with vaccines against diphtheria, tetanus, and poli-
omyelitis, and produced by the Netherlands Vaccine
Institute, Bilthoven, the Netherlands. One human dose
(HD) contains 1.6 × 1010 CFU of two B. pertussis strains
(strains 509 and 134; 8 opacity units/strain) in 1 ml
saline, and is adjuvated with 1.5 mg aluminum phos-
phate.
The aP vaccine is 3-component acellular pertussis vaccine,
combined with vaccines against diphtheria and tetanus,
and produced by GlaxoSmithKline, Rixensart, Belgium.
One HD contains 25 μg formaldehyde- and glutaralde-
hyde-detoxified pertussis toxin, 25 μg filamentous hemag-
glutinin, and 8 μg pertactin in 0.5 ml saline, and is
adjuvated with aluminum hydroxide (< 0.625 mg Al per
HD).
Vaccination
One HD wP or aP was diluted with 0.5% Al(OH)3 gel
(Serva, Heidelberg, Germany) to a final volume of 2.5 ml.
Mice (6 per group) received a subcutaneous injection with
0.5 ml of 1/5 HD wP, 1/5 HD aP, or adjuvant alone, 28
and 14 days before infection [5,13]. Note that the ratio
Effects of Tlr4 mutation in vaccine-induced immunity Figure 7
Effects of Tlr4 mutation in vaccine-induced immunity. Parameters that show a lower response in Tlr4-deficient mice 
compared to wild-type animals are represented in red, while the ones that show a higher response are represented in green. 
Parameters that are not affected or have not been determined are represented in black. Triangles represent wP, circles aP, and 
squares B. pertussis. IL-23 is put between brackets as this cytokine is able to maintain, rather than generate Th17 cells.
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c) Challenge after wP Vaccination d) Challenge after aP Vaccination
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between adjuvant and bacteria (in case of wP) or between
adjuvant and proteins (in case of aP) was considerably
higher in the murine vaccine doses than in the original
human vaccine doses.
Infection of mice and autopsy
The mice were anaesthetized with isoflurane. Two h
before infection, 3 drops of blood were collected from the
orbital plexus. A single drop of 40-μl inoculum containing
2 × 107 B. pertussis cells (Tohama strain B213) was care-
fully placed on the top of the nose and allowed to be
inhaled [33].
Mice were sacrificed 3 or 7 days after challenge, except in
case of lung pathology in which case the mice were sacri-
ficed 3 days after infection only. They were anaesthetized
with ketamine, rompun, and atropine, and blood was col-
lected from the orbital plexus. Perfusion of the right ven-
tricle was performed with 2 ml PBS supplemented with
3.5% heat-inactivated Fetal Calf Serum (FCS; PAA, Linz,
Austria). The lungs were excised and used to obtain bron-
chial lymph nodes (LN) and lung lobes. The left lung
lobes were formalin-fixed for histological examination or
collected in RNA-later (Qiagen, Venlo, the Netherlands)
for RNA extraction, while the right lung lobes were used
for enumeration of bacteria.
Lung lobes, CFU determination, and histological 
examination
A ligature was made around the right bronchus after
which the right lobes were removed for enumeration of
bacteria. The lobes were homogenized in 900 μl of Verwey
medium using a tissue homogenizer (Pro-200, ProScien-
tific, Monroe, CT) at maximum speed for 10 s. The
homogenates were diluted in Verwey medium 10- and
100-fold for the immunized mice, and 1000-fold for the
control mice. Hundred-μl aliquots of the dilutions were
plated on BG plates supplemented with streptomycin and
incubated at 35°C for 5 days.
The remaining left lung lobes were fixed intratracheally
using 4% formalin for 24 h. After overnight dehydration,
they were embedded in paraffin. Five-μm sections were
cut and stained with haematoxylin/eosin. Histological
lesions were semi-quantitatively scored as absent (0),
minimal (1), slight (2), moderate (3), strong (4), or severe
(5), respectively. This score incorporates the frequency as
well as the severity of the lesions.
Ptx-, FHA-, and Prn-specific IgG
Pertussis toxin (Ptx) and filamentous hemagglutinin
(FHA) were obtained from Kaketsuken, Kumamoto,
Japan. Pertactin (Prn1) was prepared as described previ-
ously [34]. Immulon 2HB plates (Thermo Scientific,
Waltham, MA) were coated with 2 μg/ml Ptx, 2 μg/ml
FHA, or 5 μg/ml Prn1, in PBS, incubated overnight, and
washed. After addition of a dilution series of control and
test sera, the plates were incubated for 1 h and washed.
After addition of detection antibody (1:5,000 anti-mouse
IgG-horseradish peroxidase (HRP); Southern Biotechnol-
ogy Associates, Birmingham, AL) in PBS, 0.1% Tween-80,
0.5% Protifar (Nutricia, Zoetermeer, the Netherlands),
the plates were incubated for 1 h and washed. To detect
HRP, the plates were washed and incubated for 10 min in
10% sodium acetate, 1% tetramethylbenzidine (Sigma,
Axel, the Netherlands), and 0.01% H2O2. 2M H2SO4 was
added to stop color development and the plates were read
at 450 nm. Washing steps were 5 times with PBS-0.03%
Tween-80. Incubations were at room temperature.
Cell culture
The culture medium used was RPMI-1640 (Gibco, Grand
Island, NY) supplemented with 10% FCS, 100 μg/ml
streptomycin, and 100 IU/ml penicillin. Cell suspensions
were made by pressing the LN or spleens through a cell
strainer (Falcon, Franklin Lakes, NJ). Cells were counted
using a Coulter Counter (Coulter Electronics, Luton, UK).
LN cell suspensions were cultured at 106 cells per ml cul-
ture medium with 5 μg/ml Concanavalin A (Con A; MP
Biomedicals, Irvine, CA) in flat-bottom 12-well culture
plates (Costar, Cambridge, MA) at 37°C in a humidified
atmosphere containing 5% CO2 for 24 h. Spleen cell sus-
pensions were cultured at 106 cells per ml culture medium
with 5 μg/ml Con A or B. pertussis (105 heat-inactivated
bacteria per well) in 96-well tissue culture plates (Nunc)
at 37°C in a humidified atmosphere containing 5% CO2
for 72 h. Bacteria were heat-inactivated at 56°C during 30
min.
Cytokine expression
Cytokine mRNA expression was measured using Taqman
gene expression assays (Applied Biosystems, Foster City,
CA) as described previously [4,5]. Briefly, RNA was
extracted with an RNeasy kit (Qiagen). Copy DNA was
generated using the High Capacity cDNA archive kit con-
taining random hexamer primers (Applied Biosystems).
Messenger RNA expression was measured on a 7500 Fast
Real-Time PCR System (Applied Biosystems). We used the
assay on demand (Applied Biosystems) for IL-1α
(Mm99999060), IL-1β (Mm01336189), IL-4
(Mm00445259), IL-5 (Mm00439646), IL-17
(Mm00439618), IL-23 (Mm00518984), IFN-γ
(Mm00801778), and TNF-α (Mm00443258). For the ref-
erence gene, hypoxanthine phosphoribosyl transferase
(HPRT), the assay was designed using the primer express
program (Applied Biosystems) resulting in probe CAGTC-
CTGTCCATAATCA, forward primer GCCGAGGATTT-
GGAAAAAGTGTTTA, and reverse primer
TTCATGACATCTCGAGCAAGTCTTT. The relative concen-BMC Immunology 2008, 9:21 http://www.biomedcentral.com/1471-2172/9/21
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tration of the various mRNA's was determined by the
comparative threshold cycle method (ddCt) [35-37].
The fold change in mRNA expression is relative to lung tis-
sue of untreated C57BL/6J mice. This third-party control
strain does not favor either of the two strains of mice
tested (the C3H/HeJ or the C3H/HeOuJ strain).
Cytokine measurements
An 8-plex panel containing beads for mouse IL-1α, IL-4,
IL-5, IL-10, IL-13, IL-17, IFN-γ, and TNF-α (Bio-Rad, Her-
cules, CA) was used. After incubation and washing steps
(see [5] for details) the beads were measured on a Bio-Plex
(Bio-Rad).
Statistics
One-way analysis of variance (ANOVA), followed by the
Bonferroni post-hoc test was performed (SPSS, Chicago,
IL). Changes in body weight were analyzed by paired sam-
ple testing (SPSS). Histological data were analyzed using
the non-parametric Mann-Whitney U test (SPSS).
Authors' contributions
SB carried out the infection and real-time PCR experi-
ments and helped to draft the manuscript. RMS developed
and carried out the serology. ERG carried out the cell cul-
ture and immunoassays. JAMAD evaluated the lung
pathology. FRM participated in the study design and coor-
dination. TGK conceived the study, participated in the
study design and coordination, and helped to draft the
manuscript. RJV conceived the study, participated in the
study design and coordination, and wrote the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
Dirk Elbers, Coen Moolenbeek, Piet van Schaaik, Christine Soputan, Hans 
Strootman, Sisca de Vlugt-van den Koedijk, and Sandra de Waal are 
acknowledged for excellent technical assistance. Drs. Cecile van Els and 
Kasper Hoebe are acknowledged for critical review of the manuscript.
References
1. Beutler B: Tlr4: central component of the sole mammalian
LPS sensor.  Curr Opin Immunol 2000, 12:20-6.
2. Higgins SC, Lavelle EC, McCann C, Keogh B, McNeela E, Byrne P,
O'Gorman B, Jarnicki A, McGuirk P, Mills KH: Toll-like receptor 4-
mediated innate IL-10 activates antigen-specific regulatory
T cells and confers resistance to Bordetella pertussis by inhib-
iting inflammatory pathology.  J Immunol 2003, 171:3119-27.
3. Mann PB, Wolfe D, Latz E, Golenbock D, Preston A, Harvill ET:
Comparative toll-like receptor 4-mediated innate host
defense to Bordetella infection.  Infect Immun 2005, 73:8144-52.
4. Banus HA, Vandebriel RJ, de Ruiter H, Dormans JA, Nagelkerke NJ,
Mooi FR, Hoebee B, van Kranen HJ, Kimman TG: Host genetics of
Bordetella pertussis infection in mice: significance of Toll-like
receptor 4 in genetic susceptibility and pathobiology.  Infect
Immun 2006, 74:2596-605.
5. Vandebriel RJ, Gremmer ER, Vermeulen JP, Hellwig SM, Dormans JA,
Roholl PJ, Mooi FR: Lung pathology and immediate hypersensi-
tivity in a mouse model after vaccination with pertussis vac-
cines and challenge with Bordetella pertussis.  Vaccine 2007,
25:2346-60.
6. Banus S, Bottema RW, Siezen CL, Vandebriel RJ, Reimerink J, Mom-
mers M, Koppelman GH, Hoebee B, Thijs C, Postma DS, Kimman TG,
Stelma FF: Toll-like receptor 4 polymorphism associated with
the response to whole-cell pertussis vaccination in children
from the KOALA study.  Clin Vaccine Immunol 2007, 14:1377-80.
7. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH: TLR4 mediates vac-
cine-induced protective cellular immunity to Bordetella per-
tussis: role of IL-17-producing T cells.  J Immunol 2006,
177:7980-9.
8. Geurtsen J, Banus HA, Gremmer ER, Ferguson H, de la Fonteyne-
Blankestijn LJJ, Vermeulen JP, Dormans JA, Tommassen J, Ley P van
der, Mooi FR, Vandebriel RJ: LPS analogs improve efficacy of
acellular pertussis vaccine and reduce type I hypersensitivity
in mice.  Clin Vaccine Immunol 2007, 14:821-9.
9. McVernon J, Andrews N, Slack MP, Ramsay ME: Risk of vaccine fail-
ure after Haemophilus influenzae type b (Hib) combination
vaccines with acellular pertussis.  Lancet 2003, 361:1521-3.
10. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM:
Th17: an effector CD4 T cell lineage with regulatory T cell
ties.  Immunity 2006, 24:677-88.
11. Berbers GA, Lafeber AB, Labadie J, Vermeer-de Bondt PE, Bolscher
DJ, Plantinga AD: A randomized controlled study with whole-
cell or acellular pertussis vaccines in combination with regu-
lar DT-IPV vaccine and a new poliomyelitis (IPV vero) com-
ponent in children 4 years of age in the Netherlands.  1999
[http://www.rivm.nl/bibliotheek/rapporten/105000001.pdf].
12. Redhead K, Watkins J, Barnard A, Mills KH: Effective immuniza-
tion against Bordetella pertussis respiratory infection in
mice is dependent on induction of cell-mediated immunity.
Infect Immun 1993, 61:3190-8.
13. Berg BM van den, David S, Beekhuizen H, Mooi FR, van Furth R: Pro-
tection and humoral immune responses against Bordetella
pertussis infection in mice immunized with acellular or cel-
lular pertussis immunogens.  Vaccine 2000, 19:1118-28.
14. Watanabe M, Nagai M: Reciprocal protective immunity against
Bordetella pertussis and Bordetella parapertussis in a
murine model of respiratory infection.  Infect Immun 2001,
69:6981-6.
15. Carbonetti NH, Artamonova GV, Andreasen C, Dudley E, Mays RM,
Worthington ZE: Suppression of serum antibody responses by
pertussis toxin after respiratory tract colonization by Borde-
tella pertussis and identification of an immunodominant
lipoprotein.  Infect Immun 2004, 72:3350-8.
16. Steinman L: A brief history of T(H)17, the first major revision
in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue
damage.  Nat Med 2007, 13:139-45.
17. Bettelli E, Oukka M, Kuchroo VK: T(H)-17 cells in the circle of
immunity and autoimmunity.  Nat Immunol 2007, 8:345-50.
18. Fedele G, Stefanelli P, Spensieri F, Fazio C, Mastrantonio P, Ausiello
CM: Bordetella pertussis-infected human monocyte-derived
dendritic cells undergo maturation and induce Th1 polariza-
tion and interleukin-23 expression.  Infect Immun 2005,
73:1590-7.
19. Kerfoot SM, Long EM, Hickey MJ, Andonegui G, Lapointe BM,
Zanardo RC, Bonder C, James WG, Robbins SM, Kubes P: TLR4
contributes to disease-inducing mechanisms resulting in
central nervous system autoimmune disease.  J Immunol 2004,
173:7070-7.
20. Wang ZY, Yang D, Chen Q, Leifer CA, Segal DM, Su SB, Caspi RR,
Howard ZO, Oppenheim JJ: Induction of dendritic cell matura-
tion by pertussis toxin and its B subunit differentially initiate
Toll-like receptor 4-dependent signal transduction path-
ways.  Exp Hematol 2006, 34:1115-24.
21. Chen X, Howard OMZ, Oppenheim JJ: Pertussis toxin by induc-
ing IL-6 promotes the generation of IL-17-producing CD4
cells.  J Immunol 2007, 178:6123-9.
22. Wolfe DN, Mann PB, Buboltz AM, Harvill ET: Delayed role of
tumor necrosis factor-alpha in overcoming the effects of per-
tussis toxin.  J Infect Dis 2007, 196:1228-36.
23. Takeda K, Akira S: Toll-like receptors in innate immunity.  Int
Immunol 2005, 17:1-14.
24. Zughaier SM, Zimmer SM, Datta A, Carlson RW, Stephens DS: Dif-
ferential induction of the toll-like receptor 4-MyD88-depend-
ent and -independent signaling pathways by endotoxins.
Infect Immun 2005, 73:2940-50.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Immunology 2008, 9:21 http://www.biomedcentral.com/1471-2172/9/21
Page 15 of 15
(page number not for citation purposes)
25. Jiang Z, Georgel P, Du X, Shamel L, Sovath S, Mudd S, Huber M, Kalis
C, Keck S, Galanos C, Freudenberg M, Beutler B: CD14 is required
for MyD88-independent LPS signaling.  Nat Immunol 2005,
6:565-70.
26. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, Goode J,
Lin P, Mann N, Mudd S, Crozat K, Sovath S, Han J, Beutler B: Identi-
fication of Lps2 as a key transducer of MyD88-independent
TIR signalling.  Nature 2003, 424:743-8.
27. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M,
Nakanishi K, Akira S: Targeted disruption of the MyD88 gene
results in loss of IL-1- and IL-18-mediated function.  Immunity
1998, 9:143-50.
28. Hoebe K, Janssen EM, Kim SO, Alexopoulou L, Flavell RA, Han J,
Beutler B: Upregulation of costimulatory molecules induced
by lipopolysaccharide and double-stranded RNA occurs by
Trif-dependent and Trif-independent pathways.  Nat Immunol
2003, 4:1223-9.
29. Tough DF, Sun S, Zhang X, Sprent J: Stimulation of naïve and
memory T cells by cytokines.  Immunol Rev 1999, 170:39-47.
30. Togbe D, Aurore G, Noulin N, Quesniaux VF, Schnyder-Candrian S,
Schnyder B, Vasseur V, Akira S, Hoebe K, Beutler B, Ryffel B, Couillin
I:  Nonredundant roles of TIRAP and MyD88 in airway
response to endotoxin, independent of TRIF, IL-1 and IL-18
pathways.  Lab Invest 2006, 86:1126-35.
31. McGuirk P, Mills KH: A regulatory role for interleukin 4 in dif-
ferential inflammatory responses in the lung following infec-
tion of mice primed with Th1- or Th2-inducing pertussis
vaccines.  Infect Immun 2000, 68:1383-90.
32. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell
D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli
P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and
C57BL/10ScCr mice: mutations in Tlr4 gene.  Science 1998,
282:2085-8.
33. Willems RJ, Kamerbeek J, Geuijen CA, Top J, Gielen H, Gaastra W,
Mooi FR: The efficacy of a whole cell pertussis vaccine and
fimbriae against Bordetella pertussis and Bordetella paraper-
tussis infections in a respiratory mouse model.  Vaccine 1998,
16:410-6.
34. Hijnen M, van Gageldonk PG, Berbers GA, van Woerkom T, Mooi FR:
The Bordetella pertussis virulence factor P.69 pertactin
retains its immunological properties after overproduction in
Escherichia coli.  Protein Expr Purif 2005, 41:106-12.
35. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu
C: An overview of real-time quantitative PCR: applications
to quantify cytokine gene expression.  Methods 2001,
25:386-401.
36. Ariani F, Mari F, Pescucci C, Longo I, Bruttini M, Meloni I, Hayek G,
Rocchi R, Zappella M, Renieri A: Real-time quantitative PCR as
a routine method for screening large rearrangements in
Rett syndrome: Report of one case of MECP2 deletion and
one case of MECP2 duplication.  Hum Mutat 2004, 24:172-7.
37. Swillens S, Goffard JC, Marechal Y, de Kerchove d'Exaerde A, El
Housni H: Instant evaluation of the absolute initial number of
cDNA copies from a single real-time PCR curve.  Nucleic Acids
Res 2004, 32:e561.